{"id":8004,"date":"2026-10-30T12:05:33","date_gmt":"2026-10-30T12:05:33","guid":{"rendered":"https:\/\/replyguru.online\/?p=8004"},"modified":"2026-10-30T12:05:33","modified_gmt":"2026-10-30T12:05:33","slug":"my-ldl-cholesterol-was-normal-my-apob-wasnt","status":"publish","type":"post","link":"https:\/\/replyguru.online\/?p=8004","title":{"rendered":"My LDL Cholesterol Was Normal. My ApoB Wasn\u2019t."},"content":{"rendered":"
\n<\/p>\n
\n
Sara Szal MD<\/span> <\/span><\/p>\n
For more than 30 years, I\u2019ve watched women walk out of their doctor\u2019s office holding a cholesterol report stamped \u201cnormal.\u201d I\u2019ve seen the relief settle on their faces because they had eaten the vegetables, walked the miles, shown up for every annual physical, and here was proof it had paid off. Too few doctors told them what that report left out. Even fewer investigated further to detect their more subtle risk. This spring, I found out I was one of those women who needed the deeper dive.<\/p>\n
I trained in obstetrics and gynecology, then went deep into women\u2019s cardiovascular health, because the same pattern kept walking into my office: women who did everything right, who were sent home reassured, and who never heard about the two numbers that could change how they should think about their hearts for the rest of their lives. Then they end up with an elevated coronary artery calcium score or CT angiogram, or worse yet, a heart attack, and don\u2019t understand why.<\/p>\n
Thirty-five years ago, medical school taught me to read a cholesterol panel from top to bottom: total cholesterol, LDL, HDL, and triglycerides. The method that I learned decades ago is still how most doctors read it today. About 10 years ago, I completed a two-year fellowship in advanced cardiometabolic health, where you learn to look under the hood in a more comprehensive way and order different tests, including the ones that show where a person stands right now and what needs to change. I\u2019ve tracked those numbers in my patients ever since, and in myself, including my own ApoB and Lp(a). Watching closely didn\u2019t make me exempt because menopause still moved one of them.<\/p>\n
Share<\/span><\/p>\n
I thought my heart was great. I\u2019m the doctor who once pricked her finger for a journalist\u2019s camera and narrated the wait for a cheap glucose meter like a drumroll, so sure of the result that I was celebrating before it beeped. I eat the SMASH fish and vegetables, wore a continuous glucose monitor for a decade, and exercise regularly. My LDL cholesterol has never once been flagged: 83 mg\/dL in 2024, a little lower through 2025, and 93 mg\/dL this year, every result tucked under the 100 mg\/dL line that keeps a cardiovascular lab report in the normal range.<\/p>\n
However, my ApoB told a different story. It hovered around 80 for two years. Then, within a year of my final period, it rose to 91 mg\/dL and crossed the 90 mg\/dL line the National Lipid Association uses as a treatment threshold for people at borderline or intermediate risk.[1] My LDL never raised its hand. The particle count did.<\/p>\n
What happened to me is what happens to many women at menopause. The Study of Women\u2019s Health Across the Nation (SWAN) followed more than a thousand women through their final period and found that LDL cholesterol and ApoB both jump in the year on either side of it, a shift tied to menopause itself rather than to another birthday.[2] Mine jumped on schedule. Yours might too, and if your doctor checks only LDL, the jump can hide in plain sight.<\/p>\n
I\u2019ve been humbled by my labs before. At 44, doing everything right and maybe a little smug about it, I took a biological-age test expecting good news, but I was aging faster than my calender age. Yikes. That moment, 15 years ago, got me to rebuild how I practice medicine and take the long view for female longevity, starting with myself.<\/p>\n
This time, with my ApoB drifting upward, my doctor suggested Zetia, the brand name for ezetimibe, a daily pill that keeps your gut from absorbing as much cholesterol, both from food and from the bile your liver recycles, so less of it reaches your blood. It\u2019s often added to a statin or used by people who can\u2019t take one or would rather not. In my next post, I\u2019ll tell you what I decided about his recommendation and why.<\/p>\n
Lp(a) is the one I got lucky on. Three tests over two years, and mine has never registered above the bottom of the scale, under 10 nmol\/L. It\u2019s one of the good things I inherited \u2014 though we all have vulnerabilities in our blueprint from our parents, that wasn\u2019t one of them. I did nothing to earn that, which is why I need Laura to show you the other half of this story.<\/p>\n
Laura is a women in my practice, with identifying details changed to protect her anonymity. She is 45. Three years ago, her Lp(a) came back at 54 mg\/dL, just over the line where it starts to count as high. It was the kind of result that gets a shrug. This year it came back at 70 mg\/dL, a 30% jump.<\/p>\n
Her LDL cholesterol had been climbing too, from 121 mg\/dL three years ago to 148 mg\/dL now, so on paper her heart looked like it was getting worse on two fronts at once.<\/p>\n
Then we looked at her ApoB: 86 mg\/dL, under the same 90 mg\/dL line I had just crossed.[1] So her LDL is 55 points higher than mine, but her ApoB is lower.<\/p>\n
Her numbers send mixed messages: her LDL said worry, her ApoB said less than you\u2019d think, and her Lp(a) said watch me please. To make sense of either Laura or me, you need to know what each number measures.<\/p>\n
Leave a comment<\/span><\/p>\n
LDL is a particle that carries cholesterol through your blood and can lodge in the wall of an artery. The number on your lab report, LDL cholesterol (LDL-C), measures how much cholesterol those particles are carrying, by weight. It doesn\u2019t tell you how many particles there are.[3]<\/p>\n
ApoB, short for apolipoprotein B, is a protein. Every particle that can clog an artery wears exactly one ApoB tag: LDL, its cousin VLDL, and Lp(a). Count the tags and you\u2019ve counted the particles.[3]<\/p>\n
Think of your bloodstream as a highway. LDL cholesterol tells you how much cargo is on the road, while ApoB tells you how many trucks are carrying it. Usually the two rise and fall together. Mine didn\u2019t.<\/p>\n
Lp(a) is pronounced \u201cL-P-little-a.\u201d It\u2019s an LDL-like particle with an extra protein attached, and you inherit your level from your parents. Your genes set most of it, and diet and exercise barely move it.[3][4]<\/p>\n
\n\n
<\/picture><\/div>\n<\/figure>\n<\/div>\n
Higher Lp(a) means higher heart risk, on its own, separate from your other numbers. A level of about 50 mg\/dL (125 nmol\/L) is considered high and carries roughly 40% more risk of cardiovascular disease. At about 100 mg\/dL (250 nmol\/L), the risk roughly doubles.[3]<\/p>\n
The data in women is strong. Researchers who followed nearly 28,000 healthy women for close to 30 years, in a study published this year, found that the risk of heart attack and other major cardiovascular events began to climb once Lp(a) passed about 30 mg\/dL. The women at the very top, above 131 mg\/dL, had about 74% more risk than women below the median.[5]<\/p>\n
US and European guidelines both recommend that every adult have Lp(a) measured at least once in their lifetime.[3][4]<\/p>\n
For most people, Lp(a) stays in the same general range across a lifetime.[3] Within that range, it moves more than most of us were taught. When Johns Hopkins researchers tested more than 600 people twice, about 4 in 10 saw their Lp(a) change by more than 25%, and among those who started in the borderline zone, about a third moved up into the high-risk range on the second test while a fifth moved down.[6]<\/p>\n
So a 30% jump sits within what we see. Some of that movement comes from the test itself, since labs measure Lp(a) in different ways, which is why the new US guideline calls for better-standardized assays.[3] Some of it is biology. A separate analysis from the same menopause study tracked women year by year and found that Lp(a) peaked in late perimenopause and early postmenopause, the years when estrogen falls.[7] At 45, Laura is walking into that window.<\/p>\n
Either way, her number crossed further into the zone that may signal significant risk and a shift that size deserves a deeper look.<\/p>\n
Share<\/span><\/p>\n
Most of the time, LDL cholesterol and ApoB tell the same story. When they don\u2019t, doctors call it discordance, and it\u2019s common.[1] The people most likely to carry an ApoB that runs high for their LDL are those with metabolic syndrome or high triglycerides.[8] I have neither. My triglycerides are low and my HDL is high, and a national study of US adults found that this mismatch turns up in metabolically healthy people too.[9]<\/p>\n
Laura has the opposite mismatch. Her LDL cholesterol is high, and her ApoB is lower than you\u2019d expect. In truck terms, she has a lot of cargo riding in fewer trucks, and fewer particles means fewer chances for one to lodge in an artery wall. I have modest cargo in more trucks than my LDL lets on.<\/p>\n
So which number should guide care? When LDL and ApoB disagree, the National Lipid Association concludes that heart risk generally follows ApoB, or non-HDL cholesterol, a related measure.[1] Among people already taking statins, a Copenhagen team found that Laura\u2019s pattern, a high LDL with a low ApoB, wasn\u2019t linked to more heart attacks or deaths, though because those patients were on treatment, the match to Laura isn\u2019t perfect.[10] The same group reported this year that when ApoB and non-HDL cholesterol disagree, either kind of mismatch carries more heart attack risk than having both low, and having both high carries the most.[11]<\/p>\n
For Laura, that\u2019s reassuring, and it still leaves work to do. Her risk sits closer to what her ApoB says than what her LDL says, and her ApoB count already includes her Lp(a) particles, since each one wears an ApoB tag too.[3] For me, it means my \u201cnormal\u201d LDL was the wrong number to lean on.<\/p>\n
ApoB earns its place even when the numbers seem to agree. Among more than 95,000 Danish adults not taking statins, about 1 in 10 carried enough extra ApoB, beyond what their LDL predicted, to raise their heart attack risk by roughly half, in women and in men.[12] The test is precise and well validated, and the National Lipid Association wants it used far more than it is.[1]<\/p>\n
Here\u2019s where I want to be precise with you. The new US guideline keeps LDL cholesterol as the main target. It says ApoB can sharpen the picture in selected people, especially women with high triglycerides, diabetes, or the cluster of heart, kidney, and metabolic problems doctors now call cardiovascular-kidney-metabolic syndrome, and in people whose LDL has already reached its goal.[3] For women who aren\u2019t on a cholesterol drug, it calls ApoB reasonable for refining risk and deciding when to start treatment, which is exactly where I sat this spring.[3]<\/p>\n
There\u2019s a limit, and you should know it. The evidence for ApoB rests mostly on observational and discordance studies, and the National Lipid Association has asked that future cholesterol-drug trials measure ApoB so we learn how best to treat to it.[1]<\/p>\n
Laura\u2019s numbers left one question open: had any of this already started to build up in her arteries? Her coronary artery calcium score, a quick, low-dose CT scan that looks for hardened plaque in the arteries of the heart, came back 0. Short version: CAC=0.<\/p>\n
A zero is good news because two large US studies found that people with a high Lp(a) and a calcium score of 0 had about the same 10-year risk as people with a normal Lp(a) and a score of 0, and that risk climbed most when a high Lp(a) showed up alongside a high calcium score.[13]<\/p>\n
A calcium score only sees plaque that has already hardened, so softer, younger plaque can sit there unseen. Among people with a score of 0 in the Miami Heart Study, 16% had plaque on a CT angiogram, though fewer than 1% had a significant narrowing.[14] A zero buys time. It can still miss soft plaque.<\/p>\n
We didn\u2019t treat her LDL number as the whole story, and we didn\u2019t wave off her Lp(a). We used each number for the job it does best, and we added two more steps.<\/p>\n
First, hormones. We started transdermal estradiol at 0.05 mg, with progesterone 100 mg at night. Estrogen lowers Lp(a): across 24 trials, hormone therapy lowered it by about 20% on average, and estrogen by mouth lowered it more than estrogen through the skin.[15] In those trials, the route mattered more than the dose, so we went in knowing her starting plan may not move her Lp(a) much.<\/p>\n
Hormone therapy isn\u2019t approved as an Lp(a) treatment, and I don\u2019t prescribe it for that reason alone.<\/p>\n
Second, a closer look at her arteries. We\u2019re adding a CT angiogram with AI plaque analysis, which can see the soft plaque a calcium score misses.[14] We use Cleerly. (I\u2019m not paid by the company. I use it because I find it helpful in my patients.)<\/p>\n
Plaque comes in two broad kinds. Soft plaque, which doctors call noncalcified plaque, is the younger kind. It’s a deposit inside the artery wall made of cholesterol-rich particles (the ApoB trucks that slipped through the wall and got stuck), inflammatory cells, and a fibrous cap on top. It’s still active, and it’s the kind more likely to rupture and set off the clot behind a heart attack. Calcified plaque is what soft plaque can turn into over time, as the body walls it off with calcium, the way a wound hardens into a scar. It tends to be more stable, and it’s the only kind a calcium score can see.<\/p>\n
Women and men build plaque differently. On average, women develop plaque later than men (calcium shows up about 10 years later), and at any given age they have less of it, both soft and hard. So a calcium score of zero is much more common in women, especially younger women. Over time the patterns also split. Women\u2019s plaque tends to harden into calcium faster, while men\u2019s tends to keep growing as soft plaque and to develop more of the high-risk features. But less plaque doesn\u2019t mean less danger. In women, each bit of plaque, whether soft or calcified, carries more risk than the same amount does in a man, and high-risk soft plaque predicts heart attacks and other events more strongly in women. Many women with symptoms have plaque that doesn\u2019t narrow the artery enough to show up on a standard stress test, and that plaque still counts.<\/p>\n
So Laura\u2019s CAC=0 tells us she has no hardened plaque, but it can\u2019t tell us whether she has soft plaque. In a woman her age, soft plaque is exactly the kind a calcium score would miss. We\u2019re adding a CT angiogram with AI plaque analysis, which uses contrast dye to show the artery walls themselves and can measure the soft plaque a calcium score misses. [1] We use Cleerly. (I\u2019m not paid by the company. I use it because I find it helpful in my patients.)<\/p>\n
Her Lp(a) became a reason to be stricter about everything she can change: her LDL, her blood pressure, the habits that feed both. The new US guideline handles a high Lp(a) the same way, by pushing harder on LDL.[3] Stricter doesn\u2019t mean miserable. Calorie restriction may add years to a life, but I\u2019ve never met a woman who wanted to spend those years hungry, and it isn\u2019t on Laura\u2019s plan or mine.<\/p>\n
In September, pelacarsen, the first drug built to lower Lp(a) to finish a large outcomes trial, lowered Lp(a) in more than 8,000 people who already had heart disease but didn\u2019t significantly reduce major cardiovascular events.[16][17] Several other Lp(a) drugs are still in trials.[17]<\/p>\n
Her ApoB became the number we follow, because it counts the particles that do the damage, Lp(a) included. Her LDL stays on the report as the foundation.[3] I put her estradiol, FSH, LDL, ApoB, and Lp(a) on one graph, so we can watch them move together as her hormones change. And her Lp(a) gets rechecked, so we know whether that 30% jump is a trend or a blip.<\/p>\n
This is the plan that fits Laura\u2019s body, history, and goals. While your plan may look different, I hope her case gives you ideas about what to consider and discuss with your clinician. I wrote a list of bullet points at the end for you to take to your next appointment.<\/p>\n
Leave a comment<\/span><\/p>\n
It\u2019s a health hazard to be a woman. Heart health is one of the places I see it most clearly because a woman has a heart attack about every 7 seconds. Women are 7 to 10 times more likely to die of heart disease than breast cancer. If you\u2019re more scared about breast cancer, I get it, but please be vigilant about heart disease too.<\/p>\n
Medicine tends to measure what\u2019s easy to measure and then treat the result as the answer, so a woman\u2019s cholesterol comes back in range, the patient portal shows a cheerful green dot, someone types \u201cnormal, recheck in a year,\u201d and the conversation ends there, even when she\u2019s 51 and her estrogen is falling and the particles in her blood are quietly multiplying. Nobody asks what she inherited. Nobody counts the particles. Nobody asks why a number that held still for years started moving at menopause. She leaves reassured, and the reassurance is incomplete. I know, because I was reassured too.<\/p>\n
I believe every woman deserves her Lp(a) checked in perimenopause and again after menopause, at a minimum, and her ApoB on both sides of her final period.<\/p>\n
Lp(a) also asks something of us beyond our own bodies. If you inherited it, someone in your family may share it: your mother, your sister, your daughter. A single number can open a conversation across generations, the kind women have always had about what runs in the family, this time with data behind it.<\/p>\n
Laura\u2019s numbers argued with each other until someone read all three together. Mine looked fine until someone counted the particles. Your body deserves the same attention.<\/p>\n
Share The Female Edge<\/span><\/p>\n
I know how this sounds. A California doctor counting the particles in her own blood lands somewhere between the future and a punchline, and the California health guru is a famously humorless species. I try to take the medicine seriously and myself a lot less.<\/p>\n
My new book, <\/span>The Female Edge<\/em>, describes the research on female longevity that changed my entire approach to medicine, along with the way I live now: meditation, sauna, supplements, matcha lattes, HRV and sleep tracking (and what to do with the numbers), hormone therapy plus peptides, microdosing psychedelics, and a practice of awakening. Read that list aloud in most pubs and you\u2019d lose the room. Medicine from California tends to get mocked first and adopted a few years later, and ApoB is on that path right now.<\/span><\/p>\n
Here\u2019s where I\u2019ve landed. The same diet-and-exercise advice handed to every woman will someday look the way a medieval doctor treating a fever with leeches looks to us: well-meaning, and blunt. What replaces it is medicine built on your own data, from your DNA to your hormones to your particle count, read together and over time. I\u2019ve been trying to practice that medicine a few decades early, on myself first, and the book is my attempt to give you the health advice your granddaughters will take for granted.<\/p>\n
The Female Edge<\/em> comes out March 30, 2027 and preorders really make a difference in how much the publisher invests in the book. <\/span>Preorder it here. I would really appreciate your support.<\/span><\/p>\n
This essay argues that a standard cholesterol panel misses two numbers that matter for women, especially around menopause: Lp(a), the heart risk you inherit, and ApoB, which counts the artery-clogging particles your LDL doesn\u2019t. Your own story anchors it, with an LDL that always looked normal while your ApoB crossed a treatment threshold within a year of your final period. Laura, a composite patient with the opposite pattern (high LDL, lower ApoB, and an Lp(a) that jumped 30%), shows how to read all three numbers together and what a personalized plan looks like. The piece closes with why this is a women\u2019s issue, a preview of The Female Edge, and a printable Short List of what to ask your doctor (below).<\/p>\n
\u2022 Ask for Lp(a) in perimenopause and again after menopause. Guidelines say at least once; I want two, because it can move in those years.[3][4][6][7] Write each number down with its units, since labs report it in mg\/dL or nmol\/L.<\/p>\n
\u2022 If you\u2019re approaching menopause, ask for ApoB along with your LDL, and recheck it in the year or two after your final period.[1][2]<\/p>\n
\u2022 If your Lp(a) is high, tell your blood relatives. It\u2019s inherited, and the new US guideline recommends testing first-degree relatives.[3]<\/p>\n
\u2022 Ask whether ApoB makes sense for you, especially if you have high triglycerides, diabetes, or metabolic problems, or your LDL has already reached its goal.[3]<\/p>\n
\u2022 If your LDL and ApoB disagree, ask your doctor which one they\u2019re following, and why.[1]<\/p>\n
\u2022 If your Lp(a) is high, ask whether a coronary calcium score would help sort out your risk.[13]<\/p>\n
\u2022 Keep your standard cholesterol panel. These numbers add to it.[3]<\/p>\n
\u2022 If your Lp(a) is high, use it as a reason to push harder on what you can change, starting with your LDL.[3]<\/p>\n
You\u2019ve spent years being told your labs were normal. I was told the same thing, and I\u2019m a doctor. You deserve to know what normal left out.<\/p>\n
Tell me in the comments: <\/span>has a doctor ever offered you an ApoB or Lp(a) test, or did you have to ask? What did you learn and how did it change your plan?<\/em><\/p>\n
xo, Dr. Sara<\/em><\/p>\n
Leave a comment<\/span><\/p>\n
Notes<\/strong><\/p>\n
[1] <\/strong>Soffer D, et al. \u201cRole of Apolipoprotein B in the Clinical Management of Cardiovascular Risk in Adults: An Expert Clinical Consensus From the National Lipid Association.\u201d <\/span>Journal of Clinical Lipidology<\/em> 18, no. 5 (2024): e647\u2013e663.<\/span><\/p>\n
[2] <\/strong>Matthews K, et al. \u201cAre Changes in Cardiovascular Disease Risk Factors in Midlife Women Due to Chronological Aging or to the Menopausal Transition?\u201d <\/span>Journal of the American College of Cardiology<\/em> 54, no. 25 (2009): 2366\u20132373.<\/span><\/p>\n
[3] <\/strong>Blumenthal R, et al. \u201c2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines.\u201d <\/span>Journal of the American College of Cardiology<\/em> 87, no. 19 (2026): 2624\u20132757. Also published in <\/span>Circulation<\/em>, 2026.<\/span><\/p>\n
[4] <\/strong>Mach F, et al. \u201c2025 Focused Update of the 2019 ESC\/EAS Guidelines for the Management of Dyslipidaemias.\u201d <\/span>European Heart Journal<\/em> 46, no. 42 (2025): 4359\u20134378.<\/span><\/p>\n
[5] <\/strong>Nordestgaard A, et al. \u201cThirty-Year Risk of Cardiovascular Disease Among Healthy Women According to Clinical Thresholds of Lipoprotein(a).\u201d <\/span>JAMA Cardiology<\/em>, 2026.<\/span><\/p>\n
[6] <\/strong>Harb T, et al. \u201cIntra-individual Variability in Lipoprotein(a): The Value of a Repeat Measure for Reclassifying Individuals at Intermediate Risk.\u201d <\/span>European Heart Journal Open<\/em> 4, no. 5 (2024).<\/span><\/p>\n
[7] <\/strong>Derby C, et al. \u201cLipid Changes During the Menopause Transition in Relation to Age and Weight: The Study of Women\u2019s Health Across the Nation.\u201d <\/span>American Journal of Epidemiology<\/em> 169, no. 11 (2009): 1352\u20131361.<\/span><\/p>\n
[8] <\/strong>De Oliveira-Gomes D, et al. \u201cApolipoprotein B: Bridging the Gap Between Evidence and Clinical Practice.\u201d <\/span>Circulation<\/em> 150, no. 1 (2024): 62\u201379.<\/span><\/p>\n
[9] <\/strong>Sayed A, et al. \u201cIndividual Variation in the Distribution of Apolipoprotein B Levels Across the Spectrum of LDL-C or Non-HDL-C Levels.\u201d <\/span>JAMA Cardiology<\/em> 9, no. 8 (2024): 741\u2013747.<\/span><\/p>\n
[10] <\/strong>Johannesen C, et al. \u201cApolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients.\u201d <\/span>Journal of the American College of Cardiology<\/em> 77, no. 11 (2021): 1439\u20131450.<\/span><\/p>\n
[11] <\/strong>Johannesen C, et al. \u201cNon-HDL Cholesterol and Apolipoprotein B Measures and Risk of Atherosclerotic Cardiovascular Disease.\u201d <\/span>JAMA Cardiology<\/em> 11, no. 7 (2026): 669\u2013673.<\/span><\/p>\n
[12] <\/strong>Johannesen C, et al. \u201cExcess Apolipoprotein B and Cardiovascular Risk in Women and Men.\u201d <\/span>Journal of the American College of Cardiology<\/em> 83, no. 23 (2024): 2262\u20132273.<\/span><\/p>\n
[13] <\/strong>Mehta A, et al. \u201cIndependent Association of Lipoprotein(a) and Coronary Artery Calcification With Atherosclerotic Cardiovascular Risk.\u201d <\/span>Journal of the American College of Cardiology<\/em> 79 (2022): 757\u2013768.<\/span><\/p>\n
[14] <\/strong>Nasir K, et al. \u201cCoronary Atherosclerosis in an Asymptomatic U.S. Population: Miami Heart Study at Baptist Health South Florida.\u201d <\/span>JACC: Cardiovascular Imaging<\/em> 15, no. 9 (2022): 1604\u20131618.<\/span><\/p>\n
[15] <\/strong>Anagnostis P, et al. \u201cThe Effect of Hormone Replacement Therapy and Tibolone on Lipoprotein (a) Concentrations in Postmenopausal Women: A Systematic Review and Meta-Analysis.\u201d <\/span>Maturitas<\/em> 99 (2017): 27\u201336.<\/span><\/p>\n
[16] <\/strong>Novartis. \u201cNovartis Announces Lp(a)HORIZON Phase III Topline Results for Pelacarsen in Patients With Elevated Lp(a) and Established Cardiovascular Disease (CVD).\u201d Press release, September 4, 2026.<\/span><\/p>\n
[17] <\/strong>National Lipid Association. \u201cTop Line Results From the Phase 3 Lp(a)HORIZON Trial.\u201d 2026.<\/span><\/p>\n<\/div>\n
![\"\"](\"https:\/\/substackcdn.com\/image\/fetch\/$s_!wzKW!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep\/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F804ca157-d68f-49f6-91e6-c984dc67df05_1976x1104.png)
<\/picture><\/div>\n<\/figure>\n<\/div>\n